Skip to main content
. 2016 May 31;353:i2550. doi: 10.1136/bmj.i2550

Table 1.

Characteristics of children and young people with ADHD in study of effect of treatment with methylphenidate

Arrhythmias Hypertension Myocardial infarction Ischemic stroke Heart failure
No of patients 864 396 52 67 44
Median (IQR) duration of exposure (years) 0.5 (0.1-1.3) 0.5 (0.1-1.3) 0.5 (0.1-1.1) 0.5 (0.2-1.3) 0.3 (0.1-0.8)
Median (IQR) duration of exposure before events (years) 0.04 (0-0.48) 0.04 (0-0.48) 0 (0-0.26) 0 (0-0.42) 0 (0-0.13)
Median (IQR) duration of exposure after events (years) 0.20 (0.02-0.75) 0.17 (0-0.70) 0.17 (0.04-0.91) 0.27 (0.04-0.83) 0.12 (0-0.50)
Median (IQR) age at first exposure 13 (10-15) 13 (11-15) 11 (8-14) 11 (8-14) 12 (10-16)
Median (IQR) age at first outcome 13 (10-15) 13 (10-16) 11 (8-14) 11 (8-14) 13 (9-15)
No (%) of boys 674 (78) 317 (80) 39 (75) 51 (76) 33 (75)
No (%) with congenital heart disease 46 (5.3) 31 (7.8) 3 (5.8) 2 (3.0) 7 (15.9)
No (%) with comorbidity* (ICD-10 code):
 Depressive episode (F32-F33, F34.1, F41.2) 223 (25.8) 101 (25.5) 15 (28.9) 9 (13.4) 12 (27.3)
 Tic disorders (F95) 76 (8.8) 35 (8.8) 7 (13.5) 6 (9.0) 2 (4.6)
 Emotional disorders with onset specific to childhood (F93) 77 (8.9) 31 (7.8) 5 (9.6) 8 (11.9) 5 (11.4)
 Conduct disorders (F91) 82 (9.5) 34 (8.6) 1 (1.9) 3 (4.5) 3 (6.8)
 Manic episode (F30) 7 (0.8) 2 (0.5) 0 (0) 0 (0) 0 (0)
 Bipolar affective disorder (F31) 44 (5.1) 15 (3.8) 2 (3.9) 3 (4.5) 1 (2.3)
 Mental retardation (F70-F79) 75 (8.7) 30 (7.7) 4 (7.7) 12 (17.9) 2 (4.6)
No (%) with comedication† (ATC code):
 Atomoxetine 15 (1.7) 5 (1.2) 2 (2.9) 2 (2.9) 0 (0.0)
 Antipsychotics (ATC: N05A) 114 (13.2) 55 (13.9) 7 (13.5) 5 (7.5) 2 (4.6)
 Antidepressants (ATC: N06A) 181 (21.0) 78 (19.7) 8 (15.4) 12 (17.9) 12 (27.3)
 Antiepileptics (ATC: N03A) 68 (7.9) 37 (9.3) 5 (9.6) 17 (25.4) 7 (15.9)
 Anticholinergic agents (ATC: N04A) 31 (3.6) 19 (4.8) 3 (5.8) 2 (3.0) 0 (0)
 Anxiolotics (ATC: N05B) 71 (8.2) 36 (9.1) 0 (0) 4 (6.0) 4 (9.1)

IQR=interquartile range.

*Defined as at least one diagnosis or prescription between 1 January 2008 and 31 December 2011.

†Defined as coprescription with methylphenidate during same period.